Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $5.92.

Several research firms have commented on XERS. Leerink Partners increased their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. Craig Hallum raised their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Jefferies Financial Group restated a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds have recently modified their holdings of the business. Walleye Capital LLC bought a new position in Xeris Biopharma during the third quarter worth $3,197,000. JPMorgan Chase & Co. grew its position in Xeris Biopharma by 166.2% in the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company’s stock worth $3,537,000 after purchasing an additional 651,481 shares during the last quarter. Driehaus Capital Management LLC bought a new position in shares of Xeris Biopharma during the 4th quarter worth about $2,014,000. Millennium Management LLC raised its position in shares of Xeris Biopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock valued at $6,606,000 after buying an additional 502,853 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after buying an additional 500,120 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $4.57 on Monday. The stock’s 50-day moving average is $3.64 and its two-hundred day moving average is $3.29. The stock has a market cap of $681.30 million, a PE ratio of -10.16 and a beta of 2.32. Xeris Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $4.68.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.